Werner Baumann, Bayer CEO (Malte Ossowski/SVEN SIMON/picture-alliance/dpa/AP Images)

Bay­er's next-gen drug Nube­qa aces sur­vival test in metasta­t­ic prostate can­cer, putting it in com­pe­ti­tion with gi­ants

In the bat­tle for mar­ket dom­i­nance in prostate can­cer, Bay­er’s Nube­qa has made a late en­try in­to the field but holds high hopes for even­tu­al suc­cess. New late-stage da­ta could un­der­score a sec­ond in­di­ca­tion, which would bode well for the drug’s chances.

Adding Bay­er’s Nube­qa to an­dro­gen de­pri­va­tion ther­a­py and chemother­a­py do­c­etax­el cut the risk of death by 32.5% against ADT/do­c­etax­el alone in pa­tients with metasta­t­ic hor­mone-sen­si­tive prostate can­cer, the Ger­man drug gi­ant said Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.